dasabuvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals RNA polymerase (NS5B) inhibitors 4914 1132935-63-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasabuvir sodium monohydrate
  • dasabuvir
  • dasabuvir sodium
  • exviera
  • ABT-333
Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. In a biochemical assay, dasabuvir inhibited a panel of genotype 1a and 1b NS5B polymerases. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor.
  • Molecular weight: 493.58
  • Formula: C26H27N3O5S
  • CLOGP: 4.07
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 104.81
  • ALOGS: -5.79
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 2.13 L/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.70 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK9,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,TGFBR1 23
kinase-selectivity-class ACVR2B,BRAF,GRK2,MAPK7 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 2014 FDA ABBVIE INC
Nov. 20, 2014 EMA AbbVie Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 446.62 33.87 131 4430 32386 90591500
Hyperbilirubinaemia 358.26 33.87 92 4469 13844 90610042
Hepatic failure 286.45 33.87 98 4463 39630 90584256
Ascites 242.99 33.87 91 4470 47649 90576237
Blood bilirubin increased 210.79 33.87 80 4481 43390 90580496
Hepatocellular carcinoma 174.66 33.87 37 4524 2391 90621495
Hepatic encephalopathy 131.26 33.87 42 4519 13730 90610156
Asthenia 99.85 33.87 128 4433 533623 90090263
Renal impairment 96.08 33.87 62 4499 105359 90518527
Anaemia 93.11 33.87 101 4460 352701 90271185
Vomiting 73.52 33.87 137 4424 788156 89835730
Child-Pugh-Turcotte score increased 71.64 33.87 9 4552 14 90623872
Hepatic cirrhosis 62.05 33.87 39 4522 63214 90560672
Hepatorenal syndrome 59.83 33.87 15 4546 2033 90621853
Encephalopathy 51.56 33.87 31 4530 46413 90577473
Varices oesophageal 50.73 33.87 15 4546 3764 90620122
Drug ineffective 47.02 33.87 7 4554 1384291 89239595
Yellow skin 46.54 33.87 13 4548 2668 90621218
Renal failure 46.27 33.87 44 4517 130963 90492923
Acute hepatic failure 44.39 33.87 22 4539 22539 90601347
Nausea 40.66 33.87 135 4426 1110181 89513705
Portal vein thrombosis 40.14 33.87 12 4549 3126 90620760
Hepatic cancer 38.86 33.87 13 4548 4868 90619018
Cardio-respiratory arrest 38.38 33.87 29 4532 63111 90560775

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 239.98 28.91 69 4088 8125 42609053
Ascites 204.95 28.91 103 4054 56575 42560603
Renal impairment 194.01 28.91 125 4032 110103 42507075
Hyperbilirubinaemia 156.42 28.91 63 4094 20572 42596606
Jaundice 149.24 28.91 71 4086 34518 42582660
Hepatic failure 133.88 28.91 68 4089 38032 42579146
Blood bilirubin increased 124.44 28.91 67 4090 42185 42574993
Hepatic cirrhosis 115.14 28.91 50 4107 19652 42597526
Hepatic encephalopathy 110.23 28.91 46 4111 16396 42600782
Drug interaction 68.20 28.91 105 4052 266894 42350284
Off label use 50.59 28.91 3 4154 638332 41978846
Oesophageal varices haemorrhage 45.46 28.91 16 4141 3591 42613587
Gastric varices haemorrhage 43.15 28.91 9 4148 273 42616905
Anaemia 42.67 28.91 88 4069 280190 42336988
Immunosuppressant drug level increased 39.90 28.91 18 4139 7713 42609465
Asthenia 35.68 28.91 82 4075 280711 42336467
Erosive duodenitis 34.77 28.91 11 4146 1778 42615400
Drug ineffective 33.63 28.91 10 4147 630187 41986991
Yellow skin 31.81 28.91 11 4146 2343 42614835
Encephalopathy 30.37 28.91 28 4129 41305 42575873
Hepatorenal syndrome 29.74 28.91 11 4146 2843 42614335
Gastroenteritis 29.60 28.91 19 4138 16430 42600748

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 513.45 26.98 187 8352 59049 110521711
Hyperbilirubinaemia 471.76 26.98 149 8390 30522 110550238
Ascites 412.42 26.98 181 8358 92627 110488133
Hepatocellular carcinoma 369.46 26.98 96 8443 9784 110570976
Hepatic failure 367.87 26.98 153 8386 68586 110512174
Renal impairment 291.46 26.98 181 8358 188264 110392496
Blood bilirubin increased 270.26 26.98 127 8412 75845 110504915
Hepatic encephalopathy 217.94 26.98 82 8457 28174 110552586
Hepatic cirrhosis 141.16 26.98 79 8460 67547 110513213
Anaemia 125.75 26.98 181 8358 546905 110033855
Asthenia 108.76 26.98 192 8347 688807 109891953
Drug interaction 102.63 26.98 157 8382 500026 110080734
Hepatorenal syndrome 90.35 26.98 27 8512 4570 110576190
Yellow skin 84.57 26.98 25 8514 4077 110576683
Child-Pugh-Turcotte score increased 83.37 26.98 12 8527 43 110580717
Off label use 72.86 26.98 14 8525 1500171 109080589
Oesophageal varices haemorrhage 71.67 26.98 23 8516 4922 110575838
Drug ineffective 70.13 26.98 16 8523 1520524 109060236
Encephalopathy 62.37 26.98 51 8488 81004 110499756
Renal failure 53.33 26.98 76 8463 226498 110354262
Portal vein thrombosis 52.62 26.98 20 8519 7038 110573722
Alanine aminotransferase increased 51.35 26.98 67 8472 183706 110397054
Varices oesophageal 48.64 26.98 19 8520 7196 110573564
Vomiting 48.32 26.98 167 8372 910508 109670252
Acute hepatic failure 46.22 26.98 31 8508 36437 110544323
Gastric varices haemorrhage 40.09 26.98 9 8530 492 110580268
Erosive duodenitis 38.79 26.98 12 8527 2279 110578481
Ocular icterus 37.51 26.98 15 8524 6038 110574722
Haematemesis 36.90 26.98 33 8506 59075 110521685
Immunosuppressant drug level increased 36.74 26.98 18 8521 11706 110569054
Hepatic neoplasm 36.37 26.98 13 8526 3854 110576906
Upper gastrointestinal haemorrhage 35.36 26.98 30 8509 50066 110530694
Hepatic cancer 34.58 26.98 17 8522 11139 110569621
Bilirubin conjugated increased 30.36 26.98 13 8526 6211 110574549
Decreased appetite 30.30 26.98 93 8446 475753 110105007
Hyponatraemia 29.52 26.98 57 8482 217596 110363164
Drug level increased 28.52 26.98 26 8513 47693 110533067
Nausea 28.18 26.98 177 8362 1235513 109345247
Chromaturia 28.04 26.98 21 8518 29339 110551421
Condition aggravated 27.82 26.98 11 8528 734825 109845935
Melaena 27.30 26.98 30 8509 68727 110512033
Liver transplant 27.15 26.98 11 8528 4578 110576182
Biliary colic 27.13 26.98 11 8528 4586 110576174

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AP09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA EPC N0000191257 Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
FDA MoA N0000191258 RNA Replicase Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:85180 nonnucleoside hepatitis C virus polymerase inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:64951 anti-HBV agent

Related Drugs by ATC class:

J05AP Antivirals for treatment of HCV infections 18 drugs
asunaprevirbeclabuvirboceprevirdaclatasvirelbasvirglecaprevirgrazoprevirledipasvirombitasvirparitaprevirpibrentasvirribavirin show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.38 acidic
pKa2 9.01 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8501238 Dec. 19, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10201584 May 17, 2032 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 10201542 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE N206619 Dec. 19, 2014 DISCN TABLET ORAL 9629841 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10105365 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9333204 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9744170 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein cereblon Cytosolic other Ki 5.33 CHEMBL
NS5B protein Enzyme EC50 8.74 CHEMBL

External reference:

IDSource
D10553 KEGG_DRUG
1456607-55-8 SECONDARY_CAS_RN
4034028 VANDF
CHEBI:85182 CHEBI
CHEMBL3137312 ChEMBL_ID
CHEMBL3544985 ChEMBL_ID
C588260 MESH_SUPPLEMENTAL_RECORD_UI
11270 IUPHAR_LIGAND_ID
DB09183 DRUGBANK_ID
1597381 RXNORM
30778 MMSL
31899 MMSL
d08322 MMSL
015829 NDDF
015830 NDDF
714104000 SNOMEDCT_US
714105004 SNOMEDCT_US
716018007 SNOMEDCT_US
725851005 SNOMEDCT_US
C3852512 UMLSCUI
9741 INN_ID
56640146 PUBCHEM_CID
DE54EQW8T1 UNII

Pharmaceutical products:

None